<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04551482</url>
  </required_header>
  <id_info>
    <org_study_id>2020P002511</org_study_id>
    <nct_id>NCT04551482</nct_id>
  </id_info>
  <brief_title>Oxytocin for Weight Loss in Adolescents</brief_title>
  <official_title>Oxytocin as a Neuroendocrine Therapy for Obesity in Youth</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double blind, placebo-controlled study of the effects of intranasal&#xD;
      oxytocin in youths with obesity, ages 12-18 years old. Subjects will be randomized to receive&#xD;
      intranasal oxytocin or placebo (3 sprays per nostril, 4 times per day) for 12 weeks. Study&#xD;
      visits include screening to determine eligibility, 2-part main study visits at baseline, week&#xD;
      8, and week 12, and safety check-in visits at weeks 1, 2, 4, and 6, with a safety follow-up&#xD;
      visit 6 weeks after the last dose of study drug. Study procedures include appetite,&#xD;
      behavioral, metabolic, and endocrine assessments.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In recent years there has been a dramatic increase in obesity and its complications in both&#xD;
      children and adults. Earlier treatment substantially reduces the likelihood of developing&#xD;
      complications later in life while concurrently improving quality of life and decreasing&#xD;
      mortality. Therefore, it is essential to develop safe and effective therapeutic strategies&#xD;
      for weight loss, particularly in adolescents. Oxytocin (OXT), a hypothalamic peptide hormone&#xD;
      that regulates energy balance, is a novel neuroendocrine weight-loss therapeutic in adults&#xD;
      with obesity because it simultaneously reduces energy intake and increases energy expenditure&#xD;
      and is well-tolerated. Data are currently lacking regarding effects of OXT administration in&#xD;
      adolescents with obesity.&#xD;
&#xD;
      The current study is a 12-week randomized controlled trial (RCT) of OXT vs. placebo in&#xD;
      12-18-year old adolescents with obesity. We hypothesize that OXT administration will decrease&#xD;
      weight as a consequence of decreased caloric intake and increased energy expenditure, both&#xD;
      partially mediated by reduced hypothalamic inflammation (such inflammation drives weight gain&#xD;
      by increasing food intake and reducing energy expenditure). Further, OXT will improve&#xD;
      metabolic risk markers, such as visceral and intrahepatic fat, systemic inflammation, and&#xD;
      serum lipids.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">February 2021</start_date>
  <completion_date type="Anticipated">September 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weight</measure>
    <time_frame>12 weeks</time_frame>
    <description>Mean difference in weight between Oxytocin and Placebo group after 12 weeks of treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Height</measure>
    <time_frame>Baseline</time_frame>
    <description>Measure height on a stadiometer to the nearest 0.1 cm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body mass index (BMI)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Mean difference in BMI between Oxytocin and Placebo group after 12 weeks of treatment. BMI will be calculated as weight/height2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lean mass and Fat mass</measure>
    <time_frame>12 weeks</time_frame>
    <description>Dual Energy Absorptiometry (DXA) will be used for measuring fat mass (kg) and lean mass (Kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Resting Energy Expenditure (kCal)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Assessed by Indirect calorimetry</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Obesity, Adolescent</condition>
  <condition>Oxytocin</condition>
  <arm_group>
    <arm_group_label>Oxytocin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxytocin nasal spray (24 IU nasal spray, 4 times per day for 12 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo nasal spray (24 IU nasal spray, 4 times per day for 12 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin nasal spray</intervention_name>
    <description>24 IU nasal spray, 4 times per day for 12 weeks</description>
    <arm_group_label>Oxytocin</arm_group_label>
    <other_name>Syntocin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>24 IU nasal spray, 4 times per day for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and Females, 12-18 years&#xD;
&#xD;
          -  Obesity (BMI â‰¥95th percentile for age and gender)&#xD;
&#xD;
          -  Willingness to maintain current diet and lifestyle for the duration of study&#xD;
             participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active substance abuse&#xD;
&#xD;
          -  Use of prescription or over-the-counter drugs or dietary/herbal supplements affecting&#xD;
             metabolism, blood glucose, or appetite. Metformin will be allowed if participants are&#xD;
             on a stable dose with stable weight for at least 3 months&#xD;
&#xD;
          -  Greater than 5kg weight change over 3 months;&#xD;
&#xD;
          -  Follows a nonstandard diet (e.g., gluten-free, vegan, Paleo, Atkins, raw diet,&#xD;
             macrobiotic diet)&#xD;
&#xD;
          -  Cardiovascular disease&#xD;
&#xD;
          -  Prolonged QT interval&#xD;
&#xD;
          -  Chronic gastrointestinal disorders and other inflammatory conditions&#xD;
&#xD;
          -  Epilepsy&#xD;
&#xD;
          -  Untreated thyroid disease&#xD;
&#xD;
          -  ALT or AST &gt;2.5 times upper limit of normal&#xD;
&#xD;
          -  Creatinine &gt;1.5 mg/dl&#xD;
&#xD;
          -  Hyponatremia&#xD;
&#xD;
          -  Pregnancy/breastfeeding or refusal to use contraception not containing estrogen&#xD;
             throughout the study if female and sexually active&#xD;
&#xD;
          -  Use of oral contraceptive pills&#xD;
&#xD;
          -  MRI exclusion criteria such as the presence of a pacemaker or cerebral aneurysm clips&#xD;
&#xD;
          -  Weight &gt;450 lbs due to limits for MRI and DXA scanners&#xD;
&#xD;
          -  Type 1 and type 2 Diabetes Mellitus if HbA1c &gt;8%&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Madhusmita Misra, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elizabeth A Lawson, MD, MMSc</last_name>
    <phone>617-726-3870</phone>
    <email>ealawson@partners.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth A Lawson, MD</last_name>
      <email>ealawson@partners.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 31, 2020</study_first_submitted>
  <study_first_submitted_qc>September 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2020</study_first_posted>
  <last_update_submitted>February 22, 2021</last_update_submitted>
  <last_update_submitted_qc>February 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Elizabeth Austen Lawson</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Pediatric Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

